Next Article in Journal
Use of Generics—A Critical Cost Containment Measure for All Healthcare Professionals in Europe?
Next Article in Special Issue
Overview of Histone Deacetylase Inhibitors in Haematological Malignancies
Previous Article in Journal
The Impact of Residual Symptoms in Major Depression
Open AccessReview

Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies

Roswell Park Cancer Institute, Genitourinary Program, Grace Cancer Drug Center, Buffalo, NY 14263, USA
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2010, 3(8), 2441-2469; https://doi.org/10.3390/ph3082441
Received: 16 July 2010 / Revised: 30 July 2010 / Accepted: 2 August 2010 / Published: 4 August 2010
(This article belongs to the Special Issue HDAC Inhibitors)
Advancement in the understanding of cancer development in recent years has identified epigenetic abnormalities as a common factor in both tumorigenesis and refractory disease. One such event is the dysregulation of histone deacetylases (HDACs) in both hematological and solid tumors, and has consequently resulted in the development of HDAC inhibitors (HDACI) to overcome this. HDACI exhibit pleiotropic biological effects including inhibition of angiogenesis and the induction of autophagy and apoptosis. Although HDACI exhibit modest results as single agents in preclinical and clinical data, they often fall short, and therefore HDACI are most promising in combinational strategies with either standard treatments or with other experimental chemotherapies and targeted therapies. This review will discuss the induction of autophagy and apoptosis and the inhibition of angiogenesis by HDACI, and also pre-clinical and clinical combination strategies using these agents. View Full-Text
Keywords: cancer; epigenetics; epigenetic therapy; HDAC; HDAC inhibitors; apoptosis; angiogenesis; autophagy; pre-clinical; clinical trial cancer; epigenetics; epigenetic therapy; HDAC; HDAC inhibitors; apoptosis; angiogenesis; autophagy; pre-clinical; clinical trial
Show Figures

Figure 1

MDPI and ACS Style

Ellis, L.; Pili, R. Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies. Pharmaceuticals 2010, 3, 2441-2469.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop